Publications in collaboration with researchers from Aarhus University Hospital (27)

2024

  1. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

  2. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

2023

  1. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis

    Cancer Treatment Reviews, Vol. 119

  2. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis

    Radiotherapy and Oncology, Vol. 186

2022

  1. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

    Osteoporosis International, Vol. 33, Núm. 12, pp. 2527-2536

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649

2019

  1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  2. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

2018

  1. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

  2. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371

  3. Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database

    Critical Care, Vol. 22, Núm. 1

  4. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

2017

  1. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

  2. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594

2016

  1. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks

    Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878

  2. Effets du tériparatide et du risédronate sur la DMO et la consolidation fracturaire chez des patients âgés avec fracture pertrochantérique récente: Résultats finaux d'un essai clinique randomisé de 78 semaines

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A83-A84

  3. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

    Calcified Tissue International, Vol. 99, Núm. 3, pp. 259-271

  4. Fracture rate, back pain and quality of life in patients with osteoporosis treated with teriparatide: Results of the European observational study ExFOS (Extended Forsteo® Observational Study)

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A188-A189

2013

  1. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: The European Forsteo Observational Study

    BMC Musculoskeletal Disorders, Vol. 14

2012

  1. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-Year results from the EFOS study

    Journal of Rheumatology, Vol. 39, Núm. 3, pp. 600-609